GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Reviva Pharmaceuticals Holdings RVPH · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.34

-6.53%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$19.9m

FY2018FY2025

Free cash flow

−$24.6m

FY2018FY2025

Shareholders' equity

$8.6m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross profit—————−$724,740——
Research and development$11.7m$22.9m$31.4m$18.9m$4.9m$295,150$195,744$946,301
Operating income−$20.2m−$30.8m−$39.5m−$24.3m−$10.1m−$2.4m−$376,860−$1.1m
Net income−$19.9m−$29.9m−$39.3m−$24.3m−$8.5m−$3.8m−$846,832−$1.7m
Diluted earnings per share-5.48-12.85-1.41-23.81-11.81-8.20-6.49-12.95

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$15.9m$15.5m$23.7m$18.9m$31.4m$8.8m$2,600$65.2m
Cash and short-term investments$14.4m$13.5m$23.4m$18.5m$29.7m$8.8m$193$65.2m
Total liabilities$7.3m$14.7m$18.0m$10.5m$2.7m$3.3m$6.8m$6.1m
Debt$406,875$458,154————$3.8m—
Shareholders' equity$8.6m$812,572$5.7m$8.4m$28.7m$5.5m−$6.8m$59.2m
Shares outstanding4m2m28m1m1m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$24.6m−$33.5m−$28.3m−$19.0m−$10.7m−$4.1m−$218,444−$1.1m
Capital spending−$3−$4−$3—————
Free cash flow−$24.6m−$33.5m−$28.3m−$19.0m−$10.7m−$4.1m−$218,444−$1.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$2.62trn−$3.3m−$3.6m−$4.0m−$6.1m−$6.5m−$6.3m−$8.5m
Net income−$2.45trn−$3.2m−$3.4m−$4.0m−$6.1m−$6.4m−$6.3m−$8.4m
Diluted earnings per share-185,315.39-0.24-0.93-1.11-1.67-1.77-2.69-3.59
Cash from operations−$5.92trn−$3.0m−$5.0m−$5.0m−$5.0m−$8.0m−$9.0m−$4.0m
Total assets$21.14trn$23.6m$15.9m$14.3m$11.6m$7.1m$15.5m$7.6m
Cash and short-term investments$19.89trn$22.2m$14.4m$13.2m$10.4m$5.3m—$5.6m
Debt$144.09bn$231,274$406,875—$113,246$224,300—$83,000
Shareholders' equity$15.21trn$17.4m$8.6m$4.5m−$459,147−$4.5m$812,572−$10.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-6.0%52.7%—
Net income-6.5%39.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-0.2-0.1-1.4-0.1-0.1-0.4-0.0-0.0

Share price return

Finished calendar years

20252024202320222021202020192018
Return37%-35%4%18%-63%1428%6%1%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 9 Mar 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.